Biocon-Pfizer insulin deal
Biocon seems to have found a partner in global giant Pfizer for its oral insulin, which is still under clinical trials. The deal is expected to give Pfizer exclusive marketing rights for the drug and will possibly fetch Biocon nearly $200 million.
